An integrated approach for herbal drugs to target GSK3B and its linkage with melanoma and type-2 diabetes

Glycogen synthase kinase-3 (GSK3) is known to be among the busiest kinase in most cells which have more than 100 known substrates. The current understanding of GSK3 regulated mechanisms are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β. To understand the control of GSK3 control in terms of selective phosphorylation of the substrate and why does it appear evolutionarily favorable for GSK3 to assume such a large responsibility is potentially challenging main in case of human diseases. GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we focused on it in unique way where it focused on the critical pathways and their major components which are common in the diseases type-2 diabetes and melanoma mediated by GSK3β that may contribute to its capacity to fulfill its roles in multiple signaling pathways and finally, we have targeted these GSK3 associated proteins with the herbal drugs Diosmin and Fisetin. Here, we unravel the potential links between GSK3β targets, melanoma, and type-2 diabetes and further presented pivotal herbal drugs and the targets for both the diseases mediated by GSK3β leading to the conclusion that there is no direct linkage between melanoma and type-2 diabetes but GSK3β mediates them.